Celltrion Overview
- Year Founded
-
2002
- Status
-
Public
- Employees
-
2,916
- Stock Symbol
-
068270
- Investments
-
19
- Share Price
-
$156.73
- (As of Thursday Closing)
Celltrion General Information
Description
Celltrion Inc is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company's operating segments include Biopharmaceuticals and Chemical medicine segment. Its Biopharmaceuticals segment includes products and commodities such as biopharmaceutical drugs and related product-support services. The Chemical Medicine segment covers products and commodities including various chemical medicines. It generates the majority of its revenue from the Biopharmaceuticals segment.
Contact Information
Website
www.celltrion.comCorporate Office
- 23, Academy-ro
- Yeonsu-gu
- Incheon
- South Korea
Corporate Office
- 23, Academy-ro
- Yeonsu-gu
- Incheon
- South Korea
Celltrion Stock Performance
As of 12-Nov-2026, Celltrion’s stock price is $156.73. Its current market cap is $35.7B with 228M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $156.73 | $154.15 | $101.83 - $165.52 | $35.7B | 228M | 497K | $4.74 |
Celltrion Financials Summary
As of 30-Jun-2026, Celltrion has a trailing 12-month revenue of $3.37B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 27,338,819 | 28,989,020 | 28,143,660 | 32,701,520 |
| Revenue | 3,374,876 | 2,924,873 | 2,607,158 | 1,664,639 |
| EBITDA | 1,486,233 | 1,049,468 | 759,588 | 694,118 |
| Net Income | 1,086,039 | 723,482 | 309,792 | 409,689 |
| Total Assets | 15,361,635 | 15,510,248 | 14,294,391 | 15,486,248 |
| Total Debt | 2,505,971 | 2,589,337 | 1,488,607 | 1,466,943 |
Celltrion Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Celltrion Comparisons
Industry
Financing
Details
Celltrion Competitors (22)
One of Celltrion’s 22 competitors is GSK, a Corporation company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GSK | Corporation | London, United Kingdom | ||||
| Roche | Corporation | Basel, Switzerland | ||||
| Takeda Pharmaceutical | Corporation | Tokyo, Japan | ||||
| Teva Pharmaceutical Industries | Corporation | Tel Aviv, Israel | ||||
| Samsung Biologics | Corporation | Incheon, South Korea |
Celltrion Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Celltrion Patents
Celltrion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026225873-A1 | Stable liquid pharmaceutical preparation comprising infliximab and hyaluronidase | Pending | 26-Apr-2025 | ||
| WO-2026177456-A1 | Autoinjector having ergonomic structure | Pending | 18-Feb-2025 | ||
| WO-2026121862-A1 | Method for treating tnfα-related diseases | Pending | 04-Dec-2024 | ||
| WO-2026071804-A1 | Bifidobacterium stercoris strain and uses thereof | Pending | 27-Sep-2024 | ||
| WO-2026043335-A1 | Stable pharmaceutical formulation | Pending | 22-Aug-2024 |
Celltrion Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Celltrion Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Celltrion Investments & Acquisitions (19)
Celltrion’s most recent deal was a Accelerator/Incubator with AinB. The deal was made on 10-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AinB | 10-Jun-2026 | Accelerator/Incubator | Biotechnology | ||
| Nbiocell | 09-Jun-2026 | Accelerator/Incubator | Personal Products | ||
| ImClone Systems | 31-Dec-2025 | Merger/Acquisition | Drug Discovery | ||
| Eli Lilly (Biologic Medicines Facility in Branchburg, New Jersey) | 01-Oct-2025 | Corporate Asset Purchase | Buildings and Property | ||
| I'MOK. | 15-Apr-2025 | Seed Round | Other Healthcare Services |
Celltrion ESG
Risk Overview
Risk Rating
Updated November, 05, 2026
20.11 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Celltrion Exits (4)
Celltrion’s most recent exit was on 13-Nov-2024 from Abpro. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Abpro | 13-Nov-2024 | Completed |
|
||
| Abpro | 06-Apr-2022 | Completed |
|
||
| Celltrion (Asia Pacific Primary Care Business Rights) | 10-Dec-2020 | Completed |
|
||
| Celltrion (4 Types of Over the Counter Drugs) | 01-Jan-2020 | Corporate Asset Purchase | Completed |
Celltrion Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| iQone | Versoix, Switzerland | 2013 | |
| Orchem | Ansan-si, South Korea | 1991 | |
| Celltrion GSC |
Celltrion FAQs
-
When was Celltrion founded?
Celltrion was founded in 2002.
-
Where is Celltrion headquartered?
Celltrion is headquartered in Incheon, South Korea.
-
What is the size of Celltrion?
Celltrion has 2,916 total employees.
-
What industry is Celltrion in?
Celltrion’s primary industry is Pharmaceuticals.
-
Is Celltrion a private or public company?
Celltrion is a Public company.
-
What is Celltrion’s stock symbol?
The ticker symbol for Celltrion is 068270.
-
What is the current stock price of Celltrion?
As of 12-Nov-2026 the stock price of Celltrion is $156.73.
-
What is the current market cap of Celltrion?
The current market capitalization of Celltrion is $35.7B.
-
What is Celltrion’s current revenue?
The trailing twelve month revenue for Celltrion is $3.37B.
-
Who are Celltrion’s competitors?
GSK, Roche, Takeda Pharmaceutical, Teva Pharmaceutical Industries, and Samsung Biologics are some of the 22 competitors of Celltrion.
-
What is Celltrion’s annual earnings per share (EPS)?
Celltrion’s EPS for 12 months was $4.74.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
